McDiarmid S V
Department of Pediatric and Surgery, Dumont - U.C.L.A. Liver Transplant Program, University of California, School of Medicine, USA.
Kidney Int Suppl. 1996 Jan;53:S77-84.
Actuarial five-year patient survivals after pediatric orthotopic liver transplantation (OLT) of 75 to 80% are now commonplace. However, renal dysfunction after pediatric OLT remains a serious complication and maybe broadly divided into four categories. The first is pre-existing renal disease in association with liver disease. This includes tyrosinemia with Fanconi syndrome, congenital cystic disease of the liver with associated polycystic disease of the kidney, Alagille's syndrome and primary hyperoxaluria. Second is hepatorenal syndrome. Resolution is dependent on successful OLT, although short-term dialysis may be required. Children with renal failure prior to transplantation have a significantly increased mortality. Third is peri- and early post-transplant renal impairment. The four major influences on early renal function after OLT are: (i) pretransplant renal function; (ii) early liver graft function; (iii) induction therapy with cyclosporine and tacrolimus; (iv) use of other nephrotoxic drugs. Fourth is long-term nephrotoxicity of cyclosporine and tacrolimus (FK-506). Both of these essential immunosuppressives carry the risk of long-term irreversible toxicity. In one study children, treated with cyclosporine, surviving > one year after OLT, 73% had a true GFR < 77 ml/min/1.73 m2. Children treated for > or = 24 months had a significantly lower GFR than those treated from 12 to 24 months. Half the children with a GFR < or = 50 ml/min/1.73 m2 had hypertension. Another study showed that 46% of pediatric OLT patients had a > or = 20% decrease in GFR over two to four years. FK-506 nephrotoxicity is comparable to that of cyclosporine. In a randomized control trial comparing FK-506 and cyclosporine, there was a 52% decrease in GFR over the first year in the FK-506 group, which was not significantly different to that of the cyclosporine group. In 60% of patients converted from cyclosporine to FK-506 one study showed a 50% or more drop in GFR. Both FK-506 and cyclosporine are associated with hypertension, hyperkalemia, hypomagnesemia and metabolic acidosis. In conclusion, the prognosis for long-term renal function in pediatric OLT patients is as yet unknown. Debate continues as to whether the impairment is static or progressive. Long-term follow-up studies of GFR are essential.
小儿原位肝移植(OLT)术后精算得出的五年患者生存率达75%至80%如今已很常见。然而,小儿OLT术后的肾功能障碍仍是一个严重并发症,大致可分为四类。第一类是与肝病相关的既往存在的肾病。这包括伴有范科尼综合征的酪氨酸血症、伴有相关肾多囊性疾病的先天性肝囊肿病、阿拉吉列综合征和原发性高草酸尿症。第二类是肝肾综合征。其缓解取决于OLT的成功实施,不过可能需要短期透析。移植前患有肾衰竭的儿童死亡率显著增加。第三类是围手术期及移植后早期的肾功能损害。OLT术后早期肾功能的四大影响因素为:(i)移植前肾功能;(ii)早期肝移植功能;(iii)环孢素和他克莫司的诱导治疗;(iv)其他肾毒性药物的使用。第四类是环孢素和他克莫司(FK - 506)的长期肾毒性。这两种必需的免疫抑制剂都有长期不可逆毒性的风险。在一项研究中,接受环孢素治疗、OLT术后存活超过一年的儿童,73%的真实肾小球滤过率(GFR)<77 ml/min/1.73 m²。接受治疗≥24个月者的GFR显著低于接受12至24个月治疗者。GFR≤50 ml/min/1.73 m²的儿童中有一半患有高血压。另一项研究表明,46%的小儿OLT患者在两到四年内GFR下降≥20%。FK - 506的肾毒性与环孢素相当。在一项比较FK - 506和环孢素的随机对照试验中,FK - 506组第一年的GFR下降了52%,与环孢素组无显著差异。一项研究显示,在60%从环孢素转换为FK - 506的患者中,GFR下降了50%或更多。FK - 506和环孢素都与高血压、高钾血症、低镁血症和代谢性酸中毒有关。总之,小儿OLT患者长期肾功能的预后尚不清楚。关于这种损害是静止性还是进行性的争论仍在继续。对GFR进行长期随访研究至关重要。